HELEN HESLOP to Cell- and Tissue-Based Therapy
This is a "connection" page, showing publications HELEN HESLOP has written about Cell- and Tissue-Based Therapy.
Connection Strength
0.740
-
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330.
Score: 0.174
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.152
-
Immunotherapy: opportunities, risks and future perspectives. Cytotherapy. 2014 Apr; 16(4 Suppl):S120-9.
Score: 0.094
-
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012 Sep; 9(9):510-9.
Score: 0.084
-
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 02; 30(2):338-341.
Score: 0.047
-
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies. Transplant Cell Ther. 2023 04; 29(4):228-239.
Score: 0.043
-
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
Score: 0.037
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.036
-
Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015 Oct 15; 24(R1):R67-73.
Score: 0.026
-
Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24.
Score: 0.024
-
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
Score: 0.023